Search Results for: Understanding+Chronic+

The following written comments were submitted by IFFGD president, Ceciel T. Rooker, to the US Department of Defense (DoD) in connection with a January 10, 2019 meeting of the TRICARE Beneficiary Advisory Panel (BAP) regarding the Uniform Formulary and, specifically, review of gastrointestinal agents: The International Foundation for Gastrointestinal Disorders (IFFGD) commends TRICARE and the […]

On June 26, 2000, IFFGD Founder and President Nancy J. Norton presented the following testimony on behalf of IFFGD members to the Center for Drug Evaluation and Research, Gastrointestinal Drugs Advisory Committee regarding (NDA) 21-200, Zelnorm/Zelmac (tegaserod), produced by Novartis Pharmaceuticals Corporation: Before I begin, I would just like to say that I am here […]

IFFGD Founder and President, Nancy Norton, submitted the following written statement to the House Committee on Appropriations; Subcommittee on Labor, Health and Human Services, Education and Related Agencies regarding Fiscal Year 2010 appropriations for the National Institutes of Health on May 1, 2009: Thank you for the opportunity to present this written statement regarding the […]

Nancy J. Norton, President and Co-Founder of IFFGD submitted the following written statement regarding Fiscal Year 2009 appropriations for the National Institutes of Health to the Senate Committee on Appropriations Subcommittee on Labor, Health and Human Services, Education and Related Agencies on April 28, 2008: Thank you for the opportunity to present this written statement […]